| http://www.w3.org/ns/prov#value | - te safety efficacy or tolerability in one or more such studies; the pot http://www.bio-medicine.org/inc/biomed/medicine-technology.asp http://feeds.bio-medicine.org/latest-medical-technologyDate:1/6/2014 potential for institutional review boards or the FDA or other regulatory agencies to require additional nonclinical or clinical studies prior to initiation of any planned phase 2 clinical study of
|
